ANGIODYNAMICS INC — Director's Dealing 2021

Dec 30, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ANGIODYNAMICS INC (ANGO)
CIK: 0001275187
Period of Report: 2021-09-22

Reporting Person: Nighan Warren JR (SVP Quality and Regulatory)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	33879	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Non-Qualified Stock Option (right to buy)	$15.52	2027-04-28	Common Stock (50000)		Direct
Non-Qualified Stock Option (right to buy)	$16.55	2027-07-26	Common Stock (11943)		Direct
Non-Qualified Stock Option (right to buy)	$20.93	2028-07-18	Common Stock (15221)		Direct
Non-Qualified Stock Option (right to buy)	$21.54	2029-07-17	Common Stock (10790)		Direct
Non-Qualified Stock Option (right to buy)	$9.92	2030-07-14	Common Stock (20619)		Direct
Non-Qualified Stock Option (right to buy)	$26.49	2031-07-21	Common Stock (10256)		Direct
Performance Right	$		Common Stock (4302)		Direct
Performance Right	$		Common Stock (14010)		Direct
Performance Right	$		Common Stock (7550)		Direct

Footnotes

F1: These shares of common stock of AngioDynamics, Inc. ("Common Stock") include (i) 1,195 shares of Common Stock underlying restricted stock units which vest on July 18, 2022, (ii) 1,614 shares of Common Stock underlying restricted stock units which vest in two equal annual installments on each of July 17, 2022 and 2023, (iii) 5,254 shares of Common Stock underlying restricted stock units which vest in three equal annual installments on each of July 14, 2022, 2023 and 2024, and (iv) 3,775 shares of Common Stock underlying restricted stock units which vest in four equal annual installments on each of July 21, 2022, 2023, 2024 and 2025.

F2: These stock options have fully vested and are exercisable.

F3: These stock options have fully vested and are exercisable.

F4: 75% of these stock options have fully vested and are exercisable. 25% of these stock options vest on July 18, 2022.

F5: 50% of these stock options have fully vested and are exercisable. 50% of these stock options vest in two equal annual installments on each of July 17, 2022 and 2023.

F6: 25% of these stock options have fully vested and are exercisable. 75% of these stock options vest in three equal annual installments on each of July 14, 2022, 2023 and 2024.

F7: These stock options vest in four equal annual installments on each of July 21, 2022, 2023, 2024 and 2025.

F8: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in column 3 of Table II. Between 0% and 200% of the target number will be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Any shares that do not vest at the end of the performance period will be forfeited.

F9: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in column 3 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F10: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in column 3 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.